KLRK1 and neoplasm: Some chemotherapeutic drugs can upregulate the expression of NKG2D ligands in tumor cells, thus enhancing the recognition and killing effect of effector lymphocytes, such as NK cells, on tumor cells (Butler et al., 2009).